complex is formed by an interaction between the cytosolic COOH-terminal regulatory domain of the SREBPs and the cytosolic WD40 domain of SCAP. SCAP targets the SREBPs to S1P, a membrane-bound serine protease whose active site faces the lumen of the ER and post- 
indicating that SCAP has reached the Golgi apparatus where it has been modified by Golgi mannosidase II (Kornfeld and Kornfeld, 1985) . When cells are overloaded with sterols, the N-linked sugars of SCAP remain in an endo H-sensitive form, indicating that SCAP has not reached the Golgi. In sterol-depleted cells, most of the SCAP cofractionates with ER markers even though it has been modified by Golgi enzymes . These findings have led to a model in which SCAP carries SREBP from the ER to the Golgi in steroldepleted cells, after which SCAP recycles to the ER following Site-1 cleavage. In sterol-overloaded cells, the SCAP/SREBP complex does not leave the ER and Site-1 On day 1, cells were transfected with 2 g/dish of pTK-HSV-BP2 together with 0.25 g/dish pTK-SCAP. The total amount of DNA was adjusted to 4 g/ dish with pcDNA3 empty vector and pTK mock vector. On day 2, the cells were cultured for 16 hr in medium A supplemented with 5% newborn calf lipoprotein-deficient serum and compactin/mevalonate in the absence or presence of sterols. On day 3, cells were incubated with or without 1 g/ml brefeldin A for 5 hr, after which they were harvested and fractionated as described in Figure 1 . Aliquots of membranes (6 g protein) and nuclear extracts (10 g protein) were subjected to SDS-PAGE, and immunoblot analysis was carried out with 0.1 g/ml of IgG-HSV-Tag for pTK-HSV-BP2 and 5 g/ml IgG-R139 for SCAP. Filters were exposed to film for 1 s (top and bottom panels) and 30 s (middle panel). Molecular mass standards are expressed in kilodaltons. (B) On day 0, S1P-deficient SRD-12B cells were set up at a density of 3 ϫ 10 5 cells/60 mm dish in medium B. On day 1, cells were transfected with 2 g/dish of pTK-HSV-BP2 together with 0.5 g/dish pCMV-Myc-S1P. The total amount of DNA was adjusted to 4 g/dish with pcDNA3 empty vector and pTK mock vector. On day 2, the cells were cultured for 16 hr in the absence or presence of sterols as described in (A). On day 3, cells were treated with 1 g/ml brefeldin A for 5 hr prior to harvest and fractionation. Aliquots of membranes (14 g protein) and nuclear extract (33 g protein) were subjected to SDS-PAGE, and immunoblot analysis was carried out with 0.1 g/ml of IgG-HSV-Tag for pTK-HSV-BP2 and 0.5 g/ml anti-Myc 9E10 for Myc-S1P. Filters were exposed to film for 5 s (top panel), 15 s (middle panel), and 1 s (bottom panel). Molecular mass standards are expressed in kilodaltons.
If the effect of brefeldin A on SREBP cleavage is of the Golgi complex ( Figure 3A ). This intense staining was absent in the SRD-12B cells ( Figure 3D ), indicating caused by relocation of active S1P to the ER, then brefelthat it was specific for S1P. We also observed a faint din A should relieve the requirement for SCAP. To test reticular staining pattern that appeared nonspecific this hypothesis, we measured the cleavage of epitopesince it was present in the SRD-12B cells ( Figure 3D ) tagged SREBP-2 in transfected SRD-13A cells, which as well as the CHO/pS2P cells ( Figure 3A) . Because of lack SCAP as a result of mutations in the SCAP gene this nonspecific staining, we could not determine (Figure 2A ). In the absence of SCAP and brefeldin A, whether any S1P is located in the ER. Incubation of these cells showed no nuclear SREBP-2 whether incucells with rhodamine-conjugated wheat germ agglutinin bated in the absence or presence of sterols (middle (WGA) stained the trans-Golgi network in the CHO/pS2P panel, lanes 1 and 2). Treatment with brefeldin A caused cells ( Figure 3B ) and the SRD-12B cells ( Figure 3E ). the appearance of nuclear SREBP-2, and this was not Overlay of the green S1P image with the red WGA image prevented by sterols (lanes 3 and 4). As a positive control revealed that S1P and the WGA Golgi marker colocalized for these experiments, we transfected the cells with a in CHO/pS2P cells, as indicated by the merged yellow cDNA encoding wild-type SCAP (lanes 5-8). In the abimage ( Figure 3C ). No colocalization was observed in sence of brefeldin A, the SCAP cDNA restored nuclear the SRD-12B cells, which is consistent with the absence SREBP-2, and cleavage was blocked by sterols (lanes of S1P in these cells ( Figure 3F ). 5 and 6). Brefeldin A allowed cleavage to persist in the We used the same technique to trace the fate of S1P presence of sterols (lanes 7 and 8). To confirm that in brefeldin A-treated CHO/pS2P cells (Figure 4 ). In the the nuclear SREBP-2 resulted from cleavage by Site-1 absence of brefeldin A, the anti-S1P antibody showed protease, we performed a similar experiment in SRDintense Golgi fluorescence and a small amount of reticu-12B cells, which lack S1P as a result of mutations in the lar fluorescence ( Figure 4A ). When the cells were treated S1P gene ( Figure 2B ). In the absence of S1P, brefeldin with brefeldin A, the Golgi fluorescence disappeared, A failed to cause the appearance of nuclear SREBP-2 and the reticular pattern increased ( Figure 4D ). Staining either in the absence or presence of sterols (middle with WGA revealed a Golgi pattern ( Figure 4B ), and this panel, lanes 1-4). When we cotransfected a cDNA enwas unaffected by brefeldin A ( Figure 4E ). This finding coding S1P, we restored cleavage of SREBP-2, and this is consistent with previous data showing that brefeldin was inhibited by sterols (lanes 5 and 6). Sterol suppres-A causes the cis-and medial-Golgi to collapse into the sion was blocked by brefeldin A (lanes 7 and 8). Thus, ER, but it does not affect the trans-Golgi (Lippincotttreatment of SCAP-deficient cells with brefeldin A resSchwartz et al., 1989). Overlay of the S1P and WGA cues S1P-dependent cleavage of SREBPs.
images confirmed the Golgi localization of S1P in the To study the subcellular localization of S1P directly, untreated cells ( Figure 4C ), and this was abolished in we performed double-label immunofluorescence studthe brefeldin A-treated cells ( Figure 4F ). This finding ies of CHO/pS2P cells and S1P-deficient SRD-12B cells, suggests that S1P is located in the cis-and medialwhich were derived from the CHO/pS2P cells (Figure 3) .
Golgi, but not in the trans-Golgi. When stained with an antibody against S1P, the CHO/ We previously reported that S1P is processed to three pS2P cells exhibited intense staining of a juxtanuclear forms, designated S1P-A, S1P-B, and S1P-C (Espenshade et al., 1999). The NH 2 -terminal sequences of these organelle whose appearance was consistent with that 
S1P-C is endo H resistant, implying that it has reached
H does not remove the asparagine-linked N-acetylglucosamine whereas PNGase F does. The mobility of S1P-C the medial-Golgi. All of these experiments were performed with transfected cells that overexpressed epiwas only partially increased by endo H, and none of it comigrated with the PNGase F product. These data tope-tagged S1P. To confirm that these same findings apply to endogenous S1P, we performed immunoblotindicate that all molecules of S1P-C contain at least one endo H-resistant carbohydrate chain, implying that this ting experiments with anti-S1P in nontransfected CHO cells ( Figure 5 ). As reported previously, we observed protein has reached the medial-Golgi. Similar results were obtained when the cells were incubated with ste-S1P-A, S1P-B, and S1P-C in SRD-12B cells that overexpress transfected S1P ( Figure 5A , lane 2). In contrast, rols ( Figure 5B , lanes 7-10), which is consistent with previous evidence that sterols do not affect the autocatthe nontransfected CHO cells showed only two bands, corresponding in size to S1P-A and S1P-C ( Figure 5A , alytic processing or subcellular localization of S1P (Espenshade et al., 1999). Together, these data suggest that lane 3). This indicates that S1P-C is the major form of active S1P in nontransfected cells and that S1P-B in nontransfected cells the active form of S1P, namely S1P-C, resides in the Golgi. becomes prominent only when the protein is overexpressed as a result of transfection. When CHO cell memIn addition to brefeldin A treatment, another means to relocate active S1P from the Golgi to the ER is to branes were treated with peptide N-glycosidase F SRD-12B cells, which lack endogenous S1P, and we isolated permanent clones of cells that grow in the absence of cholesterol as a result of expressing active S1P. Figure 6B shows SREBP-2 processing in the parental SRD-12B cells and the two lines of permanent transfectants, designated S1P-KDEL and S1P-KDAS. When SRD-12B cells were incubated in the absence of sterols, the amount of SREBP-2 precursor was relatively low, and no cleaved nuclear SREBP-2 was visualized ( Figure  6B, lane 1) . Addition of sterols caused an increase in the amount of precursor, and there was still no nuclear SREBP-2 (lane 2). (We previously observed low amounts of endogenous SREBP precursors in sterol-deprived SRD-12B cells (Rawson et al., 1998), which we attribute to degradation of the precursor by pathways that are independent of S1P and do not lead to release of the NH 2 -terminal fragment.) When the SRD-12B cells expressed the KDEL-terminated S1P, SREBP-2 was cleaved to the nuclear form (lane 3), and cleavage was not inhibited by sterols (lane 4). Expression of the KDAS-terminated S1P also restored SREBP-2 processing (lane 5), but in this case the SREBP-2 cleavage was abolished by sterols (lane 6). mine whether S1P-KDEL obviates the requirement for SCAP and to confirm that cleavage by S1P-KDEL requires the RSVL recognition sequence in the luminal transfect cells with a mutant form of S1P that contains loop of SREBP-2. For this purpose, we transfected an ER retention/retrieval signal. For this purpose, we SCAP-deficient SRD-13A cells with a plasmid encoding prepared a cDNA encoding S1P that was truncated just wild-type HSV-tagged SREBP-2 or a mutant version prior to the COOH-terminal transmembrane domain (Figcontaining an Ala in place of the Arg of the S1P recogniure 6A). Prior studies have shown that such a truncated tion sequence, RSVL ( Figure 7A ). In the absence of any form of S1P is catalytically active (Cheng et al., 1999) . cotransfected plasmid, the SRD-13A cells failed to genAt the COOH terminus, we inserted three copies of a erate the nuclear form of SREBP-2 (middle panel, lanes Myc epitope tag followed by the sequence Lys-Asp-2 and 3). Cotransfection of a plasmid encoding SCAP Glu-Leu (KDEL). This mutant version of S1P should be restored SREBP-2 cleavage, and this was suppressed inserted into the ER lumen. After it exits from the ER, it by sterols (lanes 4 and 5). Cotransfection of S1P-KDEL should bind to the KDEL receptor, which should transalso restored cleavage, and this was no longer support it back to the ER from the Golgi (Pelham, 1992) . As pressed by sterols (lanes 6 and 7) . The S1P-KDAS cona control, we prepared a similar construct containing struct was unable to restore cleavage in SRD-13A cells the COOH-terminal sequence Lys-Asp-Ala-Ser (KDAS), (lanes 8 and 9). The S1P-KDEL plasmid did not stimulate which is not recognized by the KDEL receptor (Munro cleavage of the R519A version of SREBP-2 (lanes 11 and 12). The bottom panel of Figure 7A shows that and Pelham, 1987). We transfected these cDNAs into 3 and 4) or pCMV-S1P(1-997)Myc-KDAS (lanes 5 and 6) were cultured for 16 hr in medium A supplemented with 5% newborn calf lipoprotein-deficient serum and compactin/mevalonate in the absence or presence of sterols, and whole-cell extracts were prepared as described in the Experimental Procedures. Aliquots of cell extract (65 g protein) were subjected to SDS-PAGE and immunoblotted with 5 g/ml of monoclonal IgG-7D4 anti-SREBP-2. Filters were exposed to film for 5 s (top panel) and 30 s (bottom panel). P and N denote the precursor and cleaved nuclear forms of SREBP-2, respectively. 3 and 4) or pCMV-S1P(1-997)Myc-KDAS (lanes 5 and 6) were cultured for 16 hr in medium A supplemented with 5% newborn calf lipoprotein-deficient serum and compactin/mevalonate in the absence or presence of sterols. Samples of medium and whole-cell extracts were prepared as described in the Experimental Procedures. Aliquots of cell extracts (40 g protein) and medium (corresponding to an equivalent amount of cells) were subjected to SDS-PAGE and immunoblotted with 2.5 g/ ml anti-Myc 9E10 antibody. Filters were exposed to film for 1 s. Molecular mass standards are expressed in kilodaltons.
(C) Secretion of S1P(1-997)Myc-KDEL or S1P(1-997)Myc-KDAS in stably transfected SRD-12B cells. SRD-12B cells (lanes 1 and 2) and SRD-12B cells stably transfected with pCMV-S1P(1-997)Myc-KDEL (lanes

S1P-C was detectable in membrane vesicles derived
Three lines of evidence support these conclusions. First, previous studies of SCAP glycosylation have shown that from the cells expressing S1P-KDEL, but not S1P-KDAS. Figure 7B shows a similar transient transfection ex-SCAP moves from the ER to the Golgi when cells are grown in the absence, but not the presence of sterols periment in S1P-deficient SRD-12B cells. In the absence of a cotransfected plasmid, these cells failed to generate . Second, S1P-C, the predominant form of active S1P, is found in or near the the nuclear form of HSV-tagged SREBP-2 (middle panel, lanes 2 and 3). Expression of wild-type S1P restored Golgi apparatus, as shown by immunocytochemistry (Figures 3 and 4) and studies of glycosylation patterns sterol-regulated cleavage (lanes 4 and 5). Expression of S1P-KDEL also restored cleavage, but there was no ( Figure 5 ). Third, retrograde transport of active S1P to the ER by two independent methods elicits unregulated suppression by sterols (lanes 6 and 7). S1P-KDAS restored cleavage to a lesser extent, and sterol suppres-SREBP processing and obviates the requirement for SCAP in SRD-13A cells (see Figure 8B ). sion was preserved (lanes 8 and 9). Neither S1P-KDEL nor S1P-KDAS permitted cleavage of the R519A version The current findings with brefeldin A provide an explanation for the earlier findings of Ridgway and Lagace of SREBP-2 (lanes 11-14) . Again, immunoblotting with anti-Myc revealed abundant S1P-C in the cells express-(Ridgway and Lagace, 1995), who observed that brefeldin A blocks sterol-mediated suppression of transcriping S1P-KDEL, but much lower amounts in the cells expressing S1P-KDAS (lower panel of Figure 7B ). These tion in CHO cells. By redistributing active S1P from the Golgi to the ER, brefeldin A eliminates the need to transdata indicate that expression of S1P-KDEL in the ER bypasses the SCAP requirement for SREBP cleavage.
port SREBPs to the Golgi, allowing cleavage of SREBP in the presence as well as absence of sterols. This conclusion is supported by the demonstration that a similar Discussion effect can be achieved by attaching a KDEL signal to S1P, thereby trapping it in the ER. The current results support the hypothesis that cleavage of SREBPs at Site-1 requires vesicular transport of The current studies also provide information about the Site-2 protease (S2P), which cleaves the NH 2 -terminal SREBPs from the ER to the Golgi and that this transport is blocked by sterols. The key to regulated transport is intermediate form of SREBPs that is produced by cleavage at Site-1. If Site-1 cleavage normally occurs in a SCAP, which forms a tight complex with SREBPs. In sterol-depleted cells, SCAP escorts SREBP to a postGolgi compartment, then S2P must also be located in this compartment or a more distal compartment in the ER compartment that contains active S1P (see model in Figure 8A ). In the presence of sterols, the SCAP/ secretory pathway. When Site-1 cleavage takes place in the ER, as in brefeldin A-treated wild-type CHO cells, SREBP complex remains in the ER, and SREBP never reaches the compartment that contains active S1P.
it is followed by Site-2 cleavage, thereby generating the 1-3, and 10) , pCMV-S1P-Myc (0.25 g/dish; lanes 4 and 5), pCMV-S1P(1-997)Myc-KDEL (0.25 g/dish; lanes 6, 7, 11, and 12), or pCMV-S1P(1-997)Myc-KDAS (0.25 g/dish; lanes 8, 9, 13, and 14) as indicated. The total amount of transfected DNA was adjusted to 3.75 g/dish by the addition of pTK empty vector and pcDNA3 empty vector. Cells were cultured and harvested as described in (A). Aliquots of membranes (4 g protein) and nuclear extracts (11 g protein) were subjected to SDS-PAGE and immunoblotted with 0.5 g/ml IgG-HSVTag antibody (top and middle panels) or 2.5 g/ml anti-Myc 9E10 antibody (bottom panel). Filters were exposed to film for 1 s. P and N denote the precursor and cleaved nuclear forms of SREBP-2, respectively. Molecular mass standards are expressed in kilodaltons. nuclear form of SREBP (Figure 1 ). This implies either (Figures 6 and 7) . In this case, Site-2 cleavage might have been catalyzed by the fraction of active S2P that that some active S2P normally resides in the ER or that S2P is translocated there along with S1P following breresides in the ER, or the cleaved intermediate form of SREBP might have left the ER and reached the Golgi feldin A treatment. We also generated the nuclear form of SREBP after cleavage by the KDEL-terminated S1P compartment where S2P resides. If active S1P and S2P are both located in the same carrier vesicles that are targeted to a particular organelle. This situation would be analogous to the function compartment, this compartment is in or near the Golgi, as indicated by immunofluorescence studies (Figure 3) . of cell surface clathrin-coated pits, which are common carriers whose cargo is selected by sorting molecules. This compartment has the properties of the cis-or medial-Golgi stacks in that it collapses into the ER following treatment with brefeldin A (Figure 4) proteins for incorporation into a single set of common per dish using the lipofectamine method as described previously the SuperSignal CL-HRP substrate system (Pierce) according to the manufacturer's instructions. Gels were calibrated with prestained (Sakai et al., 1998b). On day 2, the medium was switched to medium A supplemented with 5% fetal calf lipoprotein-deficient serum (conmolecular mass markers (Bio-Rad). Filters were exposed to X-Omat Blue XB-1 film (Kodak) at room temperature for the indicated times. taining no added cholesterol). The medium was changed as needed for 12 days until individual colonies were visible. Stable expression of either S1P(1-997)Myc-KDEL or S1P(1-997)Myc-KDAS permitted Glycosidase Sensitivity of S1P growth of SRD-12B cells in the absence of exogenous cholesterol.
SRD-12B and CHO/pS2P cells were cultured in medium A suppleSingle-cell clones that stably expressed S1P(1-997)Myc-KDEL and mented with 5% newborn calf lipoprotein-deficient serum, 50 M S1P(1-997)Myc-KDAS were isolated by limiting dilution and compactin, and 50 M mevalonate in the absence or presence of screened for S1P expression by immunoblotting with anti-Myc sterols (1 g/ml 25-hydroxycholesterol plus 10 g/ml cholesterol (clone 9E10) monoclonal antibody. Two cell lines expressing equivaadded in a final concentration of 0.2% ethanol). After 16 hr, ALLN lent levels of S1P(1-997)Myc-KDEL and S1P(1-997)Myc-KDAS were was added to a final concentration of 25 g/ml, and the cells were selected for further studies and designated S1P-KDEL and S1P-harvested 1 hr later. Membrane and nuclear extract fractions were KDAS cells, respectively. Harlow and Lane, 1999). Peptides were conjugated to SulfoLink was performed as previously described . Cells Coupling Gel (Pierce) according to the manufacturer's instructions. were incubated at 37ЊC for 16-24 hr in medium A supplemented For the brefeldin A experiment, cells were treated with brefeldin A with 5% fetal calf serum. On day 2, the medium was removed, and at a final concentration of 2 g/ml in 0.2% methanol for 1 hr prior the cells were cultured in medium A supplemented with 5% newborn to fixation of cells. calf lipoprotein-deficient serum, 50 M compactin, and 50 M sodium mevalonate in the absence or presence of sterols (1 g/ml
